Tibet Weixinkang Medicine Co Ltd (603676) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.009x

Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.68 Million ≈ $2.00 Million USD) by net assets (CN¥1.53 Billion ≈ $223.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Tibet Weixinkang Medicine Co Ltd worth for the company's overall valuation and market capitalisation.

Tibet Weixinkang Medicine Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tibet Weixinkang Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tibet Weixinkang Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Tibet Weixinkang Medicine Co Ltd to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Fastighetsbolaget Emilshus AB ST:EMIL-B	0.019x
Sporton International TWO:6146	0.057x
Medikaloka Hermina PT JK:HEAL	0.032x
Great Lakes Dredge & Dock NASDAQ:GLDD	0.098x
Concord Securities Co Ltd TWO:6016	-0.162x
Universal Cement Corp TW:1104	0.030x
Guilin Tourism Corp Ltd SHE:000978	0.059x
Guangzhou Grandbuy Co Ltd SHE:002187	0.021x

Annual Cash Flow Conversion Efficiency for Tibet Weixinkang Medicine Co Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. View Tibet Weixinkang Medicine Co Ltd stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥1.48 Billion ≈ $216.04 Million	CN¥185.53 Million ≈ $27.15 Million	0.126x	-53.30%
2024-12-31	CN¥1.39 Billion ≈ $202.73 Million	CN¥372.78 Million ≈ $54.55 Million	0.269x	+40.51%
2023-12-31	CN¥1.34 Billion ≈ $196.13 Million	CN¥256.67 Million ≈ $37.56 Million	0.191x	-5.04%
2022-12-31	CN¥1.22 Billion ≈ $178.61 Million	CN¥246.15 Million ≈ $36.02 Million	0.202x	+26.10%
2021-12-31	CN¥1.07 Billion ≈ $156.17 Million	CN¥170.69 Million ≈ $24.98 Million	0.160x	+17.61%
2020-12-31	CN¥983.21 Million ≈ $143.87 Million	CN¥133.70 Million ≈ $19.56 Million	0.136x	+18.93%
2019-12-31	CN¥930.05 Million ≈ $136.10 Million	CN¥106.34 Million ≈ $15.56 Million	0.114x	+23.41%
2018-12-31	CN¥897.64 Million ≈ $131.35 Million	CN¥83.17 Million ≈ $12.17 Million	0.093x	+25.59%
2017-12-31	CN¥858.04 Million ≈ $125.56 Million	CN¥63.30 Million ≈ $9.26 Million	0.074x	-67.34%
2016-12-31	CN¥459.42 Million ≈ $67.23 Million	CN¥103.79 Million ≈ $15.19 Million	0.226x	-20.48%
2015-12-31	CN¥402.93 Million ≈ $58.96 Million	CN¥114.47 Million ≈ $16.75 Million	0.284x	-31.35%
2014-12-31	CN¥286.28 Million ≈ $41.89 Million	CN¥118.47 Million ≈ $17.34 Million	0.414x	+15.75%
2013-12-31	CN¥247.78 Million ≈ $36.26 Million	CN¥88.59 Million ≈ $12.96 Million	0.358x	--

About Tibet Weixinkang Medicine Co Ltd

SHG:603676 China Drug Manufacturers - Specialty & Generic

Market Cap

$575.65 Million

CN¥3.93 Billion CNY

Market Cap Rank

#11690 Global

#3363 in China

Share Price

CN¥9.04

Change (1 day)

+0.00%

52-Week Range

CN¥8.04 - CN¥12.00

All Time High

CN¥24.05